A look at why a potential buyout of Acadia might not be as likely as some have suggested.
Acadia Pharmaceuticals (ACAD) is a small pharmaceutical company which currently markets Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis and is also developing the drug in additional indications. The aim of this article is to discuss the HARMONY study, ACAD’s other studies, and why a potential buyout of ACAD might not be as likely as some have suggested.
While current sales of Nuplazid are hardly lackluster (2017 guidance for net sales of $124-127 million), they fall short of explaining ACAD’s current $3.5-billion market cap.
